Jasper Therapeutics, Inc.

NasdaqCM:JSPR Stock Report

Market Cap: US$329.3m

Jasper Therapeutics Future Growth

Future criteria checks 2/6

Jasper Therapeutics's earnings are forecast to decline at 13.5% per annum while its annual revenue is expected to grow at 75.8% per year. EPS is expected to grow by 7.2% per annum.

Key information

-13.5%

Earnings growth rate

7.2%

EPS growth rate

Biotechs earnings growth30.0%
Revenue growth rate75.8%
Future return on equityn/a
Analyst coverage

Good

Last updated15 Aug 2024

Recent future growth updates

Recent updates

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Oct 14
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Aug 12

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jun 19
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

NasdaqCM:JSPR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261-99-92-939
12/31/20254-77-73-7710
12/31/2024N/A-62-56-5610
6/30/2024N/A-62-56-56N/A
3/31/2024N/A-64-58-57N/A
12/31/2023N/A-64-52-52N/A
9/30/2023N/A-61-48-48N/A
6/30/2023N/A-55-46-46N/A
3/31/2023N/A-50-43-42N/A
12/31/2022N/A-38-46-46N/A
9/30/2022N/A-34-49-48N/A
6/30/2022N/A-25-47-45N/A
3/31/2022N/A-23-43-42N/A
12/31/2021N/A-31-36-34N/A
9/30/2021N/A-32-26-24N/A
6/30/2021N/A-39-27-25N/A
3/31/2021N/A-40-24-23N/A
12/31/2020N/A-32-18-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: JSPR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: JSPR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: JSPR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: JSPR's revenue (75.8% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: JSPR's revenue (75.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if JSPR's Return on Equity is forecast to be high in 3 years time


Discover growth companies